Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management
- 10 January 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 6 (1) , 57-70
- https://doi.org/10.1586/14779072.6.1.57
Abstract
Oral anticoagulation therapy with warfarin is the mainstay of prevention and treatment of thromboembolic disease. However, it remains one of the leading causes of harmful medication errors and medication-related adverse events. The beneficial outcomes of oral anticoagulation therapy are directly dependent upon the quality of dose and anticoagulation management, but the literature is not robust with regards to what constitutes such management. This review focuses on, and attempts to define, the parameters of high-quality anticoagulation management and identifies the appropriate outcome measures constituting high-quality management. Elements discussed include the most fundamental measure, time in therapeutic range, along with other parameters including therapy initiation, time to therapeutic range, dosing management when patients are not in therapeutic range, perioperative dosing management, patient education, and other important outcome measures. Healthcare providers who manage oral anticoagulation therapy should utilize these parameters as a measure of their performance in an effort to achieve high-quality anticoagulation management.Keywords
This publication has 81 references indexed in Scilit:
- The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillationThrombosis Research, 2007
- Clinical outcomes with unfractionated heparin or low‐molecular‐weight heparin as bridging therapy in patients on long‐term oral anticoagulants: the REGIMEN registryJournal of Thrombosis and Haemostasis, 2006
- Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarinThrombosis and Haemostasis, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Prospective dosing of warfarin based on cytochrome P-450 2C9 genotypeThrombosis and Haemostasis, 2005
- Warfarin dosing and cytochrome P450 2C9 polymorphismsThrombosis and Haemostasis, 2004
- Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarinThrombosis and Haemostasis, 2004
- A Comparison Between Six- and Four-Week Intervals in Surveillance of Oral Anticoagulant TreatmentAmerican Journal of Clinical Pathology, 2003
- The management of anticoagulation during noncardiac operations in patients with prosthetic heart valvesAmerican Heart Journal, 1978
- Studies on Coumarin Anticoagulant DrugsCirculation, 1968